Clinical study of trotansetron combined with dexamethasone or dexmedetomidine in prevention of postoperative nausea and vomiting in high-risk PONV patients after VATS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061360

Enrollment

Unknown

Registered

2022-06-21

Start date

2022-07-11

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Tumor

Interventions

Control Group:Tropisetron was given 5 mg before the end of the operation

dexamethasone Group :Dexamethasone 5 mg was induced and Tropisetron 5 mg was given before the end of operation

dexmedetomidine group:Intraoperative intravenous infusion of 0.4 ug/kg Dexmedetomidine 10 ml, 5 mg of tropisetron before the end of the operation

Eligibility

Sex/Gender

Female

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: The people with VATS. Female non-smoker, ASA grade I-II, weight 25-65 years old, weight 45-75 kg, medium and high risk patients with PONV risk score

Exclusion criteria

Exclusion criteria: History of allergy to narcotic drugs, sulfonamides and other drugs, hypotension and Bradycardia, atrioventricular block, chronic kidney disease acidosis, intestinal obstruction or possible development of intestinal obstruction; Severe heart failure and severe hypertension.

Design outcomes

Primary

Measure	Time frame
Vomiting score;	—

Secondary

Measure	Time frame
VAS;24h number of vomiting;24h number of nausea;	—

Countries

China

Contacts

Public ContactLuJun

West China Hospital of Sichuan University

18980601978@163.com18980601978

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026